Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Small Cell Lung Carcinoma 7Lung Neoplasms 3Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Solid Tumors 1Sarcoma 1Platinum-Resistant Lung Small Cell Carcinoma 1Neutropenia 1Neuroendocrine Tumors 1Mesothelioma, Malignant 1Mesothelioma 1Gastrointestinal Malignancies 1Desmoplastic Small Round Cell Tumor 1Carcinoma, Transitional Cell 1Breast Neoplasms 1Advanced Solid Tumors 1Adenoma, Islet Cell 1

Interventions

Paclitaxel 2Injections 2toripalimab 1tislelizumab 1surufatinib 1sotorasib 1osimertinib 1netrin-1 inhibitor NP137 1lazertinib 1fluzoparib 1camrelizumab 1Panitumumab 1PM 01183 1Nivolumab 1Ipilimumab 1HMPL-013 1Erlotinib Hydrochloride 1Dexamethasone 1Calcium Dobesilate 1Bortezomib 1Bevacizumab 13-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Advanced Solid Tumors × PM 01183 × Clear all
NCT02454972 2023-03-02

Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors

PharmaMar

Phase 2 Completed
345 enrolled 34 charts 1 FDA
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡